The company’s shares have risen 58.9% year to date compared with the industry’s 12% growth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.ĪLGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. Īlign Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%.
#Cgm findings free
( HQY Quick Quote HQY - Free Report) and McKesson Corporation ( MCK Quick Quote MCK - Free Report). Some better-ranked stocks in the broader medical space are Align Technology ( ALGN Quick Quote ALGN - Free Report), HealthEquity, Inc. Quote Zacks Rank & Stocks to ConsiderĭexCom currently carries a Zacks Rank #3 (Hold). The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth.ĭexCom, Inc. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. The same month, DexCom announced better-than-expected second-quarter results. DexCom Canada is working to make DexCom G7 available to diabetic Canadians by the end of 2023. Although approved by Health Canada, DexCom G7 is not yet available for purchase. In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada’s approval for people with all types of diabetes, aged two years and above. The company had added Omnipod AID to its CGM ecosystem in the U.K. Notable DevelopmentsĮarlier this month, DexCom announced that its DexCom G6 CGM system will now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. Given the market potential and increased adoption among GLP-1 users, DexCom’s CGM business is likely to perform well in the future. Factors like the growing cases of diabetes, coupled with the increasing adoption CGM devices, are expected to drive the market. Per a report by Grand View Research, the CGM devices market was valued at $7.82 billion in 2022 and is anticipated to witness a CAGR of 4.4% from 2023 to 2030. However, investors should keep a watch on sales figure for these devices to get a clear picture of the competition landscape. With rising adoption of DexCom devices by GLP-1 users, the potential impact of GLP-1 competition is likely to diminish. The presented facts imply that adoption of CGM devices is likely to continue going forward. Moreover, the use of these devices help increase the durability of health outcomes.
The simplicity of CGM systems is supporting its accelerated adoption, even for patients on GLP-1 therapy. The company believes that the use of CGMs help patients to achieve dose titration for therapeutic regimen, as recommended in GLP-1 labeling. The use of CGMs also increased in patients on non-insulin therapy by 4.2 times. Per the data provided, use of these monitoring devices doubled on average for patients on intensive insulin while the same was up 3.8 times for patients on basal insulin alone. These devices are often paired with insulin pumps.ĭexCom presented that the use of CGMs have increased across all segments of patients with type II diabetes after beginning treatment with GLP-1 drugs. While GLP-1 are drugs that are prescribed with specific doses within regular intervals, CGM devices are worn on the body and can measure blood sugar in real time. Image Source: Zacks Investment Research DexCom Findings The S&P 500 Index has gained 17.2% in the same time frame. Shares of DexCom have lost 5.3% year to date compared with the industry’s 4.8% decline. This caused DXCM’s shares to rise in the previous week. However, DexCom stated in its presentation last week that it has surveyed and observed rising adoption of its CGM devices among patients initiating GLP-1 therapy, contradicting the assumptions. The potential rise in competition from GLP-1 drugs is an overhang for CGM-makers like DexCom, with analysts assuming negative impact over the next six months to a year. Some analysts believed that total addressable markets for CGM devices is cut meaningfully with the rising adoption of these drugs. These GLP-1 drugs, which were first approved for treating type II diabetes, are currently gaining popularity as obesity treatment. Last week, the company presented a positive picture for its continuous glucose monitoring (CGM) devices, allaying investors’ fears about rising competition from GLP-1 drugs like Wegovy, Ozempic and Mounjaro. DexCom's ( DXCM Quick Quote DXCM - Free Report) shares have risen 6.9% since Tuesday last week, while yesterday’s after-market movement took the rally to nearly 8%.
0 kommentar(er)
